Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Financial Statements Strategic CRISPR & Gene Editing Technology ETF XDNA

The investment seeks to track the total return performance of the Strategic CRISPR & Gene Editing Technology Index. The adviser employs a ¿passive management¿ investment approach designed to track the total return performance of the index. The index is a rules-based index that consists of the stocks or corresponding depositary receipts of companies engaged in the creation, development, production, operation, provision, distribution, ownership, servicing, licensing, leasing or franchising of at least one of the DNA Modification Technology Business. The fund invests at least 80% of its net assets in DNA Modification Technology Companies. It is non-diversified.


Financial Statements for (NDAQ:XDNA)